Physician profile
Dror Paley
NPI 1851334569
$3,066,094.22
in general payments reported to CMS, 2019-2025
24 companies · $256K in 2025
The $256K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355K · 2020: $156K · 2021: $673K · 2022: $571K · 2023: $617K · 2024: $438K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.3M · Food and Beverage: $1,221 · Consulting Fee: $1,200 · Travel and Lodging: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,308,224.91 |
| Food and Beverage | $1,220.90 |
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $762.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive Specialized Orthopedics, INC. | $1,370,367.91 | 2019-2023 | Precice Intramedullary Limb Lengthening System |
| Orthopediatrics Corp. | $936,030.66 | 2019-2025 | |
| Globus Medical, INC. | $230,069.55 | 2024-2025 | Precice Intramedullary Limb Lengthening System, Precice® Intramedullary Limb Lengthening System, Anthem |
| Devise Ortho INC | $220,000.00 | 2020-2021 | |
| Orthopediatrics Canada Ulc | $204,591.56 | 2022-2024 | |
| Smith+Nephew, INC. | $100,253.80 | 2019-2025 | Evos, Evos Mini, Smart Tsf |
| Vilex LLC | $3,833.19 | 2020-2021 | |
| Depuy Synthes Sales INC. | $223.03 | 2020-2023 | Na |
| Southern Edge Orthopaedics, INC. | $172.39 | 2025 | |
| Axogen | $134.93 | 2019 | |
| Nuvasive, INC. | $97.32 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $53.87 | 2025 | |
| Stryker Corporation | $46.85 | 2022 | |
| Innovation Technologies INC | $30.12 | 2025 | Irrisept |
| Checkpoint Surgical, INC | $27.03 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $23.88 | 2020 | |
| Kci USA, INC. | $23.74 | 2023 | V.A.C. Veraflo Cleanse Choice, Prevena, Snap |
| Kerecis Limited | $22.97 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Abbott Laboratories | $22.62 | 2019 | |
| Solventum Corporation | $22.25 | 2025 | Prevena, V.A.C.Instill |
| Pacira Pharmaceuticals Incorporated | $20.35 | 2022 | |
| Zimmer Biomet Holdings, INC. | $13.79 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,698,548.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dror Paley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.